This week we dig into a standout moment for women’s health diagnostics: BillionToOne’s Nasdaq listing, which priced above range and signals a tentative thaw in the healthcare IPO market.
We look at what this debut suggests for capital formation and why it matters for precision diagnostics spanning women’s health and oncology.
BillionToOne (BLLN) raised $273.1M in its IPO and was valued at $4.4B after the firm's shares jumped 66.7% in their Nasdaq debut on November 6th. The book was led by J.P. Morgan, Piper Sandler, Jefferies, and William Blair.
BillionToOne develops single-molecule sequencing assays used in non-invasive prenatal testing (UNITY) and oncology (Northstar). The technology aims to quantify low-abundance variants of inherited diseases, expanding actionable insights in prenatal screening and improving signal detection for cancer applications.
The global prenatal testing market (with NIPT as the fastest-growing slice) is commonly sized in the billions today and projected to expand over the next several years as guidelines broaden, average maternal age rises, and payers widen coverage. Within that, non-invasive prenatal testing has been scaling at a meaningfully faster clip than traditional screens due to higher detection rates and fewer invasive follow-ups, creating attractive recurring test volumes and predictable reimbursement. While exact figures vary by methodology the directional takeaway is clear: prenatal genomics is a large, durable category with room for differentiated technology.
If public markets continue to reward diagnostics platforms that combine technical differentiation with payer traction and repeat testing volumes, we expect more capital to flow into women’s health genomics (prenatal, maternal, fertility) and oncology liquid biopsy. BillionToOne’s positive public financial reception bodes well for precision-medicine women’s health companies.
BillionToOne’s above-range pricing and scale at IPO are a constructive marker for the diagnostics category and a useful datapoint for founders weighing a path back to public markets.
Emerging women’s health diagnostics platforms are gaining momentum and funding. Here are some examples of emerging innovation:
Juniper Genomics (Amboy Street Portfolio Company; Seed) - whole genome sequencing for embryos as an addition to PGT-A testing
Mirvie (Series B) - Diagnostic blood test for early detection of preeclampsia and preeclampsia risk scoring
AOA Dx (Series A) - Diagnostic blood test for early detection of ovarian cancer
.jpg)
